OCT-Angiography and Adaptive Optics in Patients With Memory Impairment
Recruiting · NCT04389437 · Interventional (participants receive a specific treatment) · Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Studies suggest an association between retinal abnormalities and NCD (Neuro Cognitive Disorders) whether they are linked to proven or prodromal Alzheimer's disease (aMCI : amnestic mild cognitive impairment), or to other neurodegenerative diseases such as frontotemporal dementia or Lewy body diseases. These retinal anomalies objectified by OCT-A (Optical coherence tomography angiography) and adaptive optics (AO) appear different depending on the pathologies and could therefore serve as markers in vivo of the pathophysiological processes underlying NCD. No study to date has studied the retina and its vessels in NCD using adaptive optics. In this pilot study, we are proposing a combination of two new ophthalmological imaging techniques (OCT-A and AO), which allow rapid in vivo analysis in a completely non-invasive way of the morphology of small vessels as well as architecture of the retina to better specify the retinal anomalies associated with NCD. We will compare the parameters in OCT-A and AO between patients with NCD and controls without NCD (with memory complaint or without) and will seek to determine if there are different profiles according to the causes of NCD.
Who can take part
Inclusion criteria
- Patient presenting in memory consultation for memory complaint or person accompanying a patient in memory consultation for memory complaint
Exclusion criteria
- pregnant or lactating women
- history of known non-degenerative neurological pathology (tumor, stroke territorial, in particular multiple sclerosis)
- history of retinal pathology
- ametropia greater in absolute value than 3 diopters on the sphere, or/and 1.5 diopters on the cylinder.
- history of taking ethambutol for more than 2 months
- history of takingsynthetic antimalarial for more than 2 years
- Mini Mental State Score (MMS) and / or Montreal Cognitive Assessment (MoCA) \<10 for patients and 26 for accompanying persons
- MRI contraindication (for patients only)
Where it is running
1 location listed.
- Hôpital Fondation A. de Rothschild - Paris, France